Active substance
Epinastine
- SFDA 1
- US FDA 7
- US price lines 1
- NHS prices 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| RELESTAT 0.05% EYE DROPS | 0.05 % | Eye drops, solution · Ophthalmic use | 1 Dropper Container | SAR 26.20 | NCE · Prescription | ABBVIE LIMITED | Valid |
Indications — CHI Daman Drug Formulary
ALLERGIC RHINITIS-ALLERGIC RHINO-CONJUNCTIVITIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| EPINASTINE HYDROCHLORIDE | 0.05% | solution/drops · ophthalmic | SOMERSET THERAPS LLC | Prescription | 31 Oct 2011 |
| ELESTAT | 0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | solution/drops · ophthalmic | ALLERGAN | Discontinued | 16 Oct 2003 |
| EPINASTINE HYDROCHLORIDE | 0.05% | solution/drops · ophthalmic | PHARMOBEDIENT | Discontinued | 14 Mar 2011 |
| EPINASTINE HYDROCHLORIDE | 0.05% | solution/drops · ophthalmic | APOTEX | Discontinued | 31 Oct 2011 |
| EPINASTINE HYDROCHLORIDE | 0.05% | solution/drops · ophthalmic | SUN PHARM INDS | Discontinued | 31 Oct 2011 |
| EPINASTINE HYDROCHLORIDE | 0.05% | solution/drops · ophthalmic | CHARTWELL RX | Discontinued | 7 Dec 2016 |
| EPINASTINE HYDROCHLORIDE | 0.05% | solution/drops · ophthalmic | EPIC PHARMA LLC | Discontinued | 5 May 2017 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | EPINASTINE HCL 0.05% EYE DROPS | $14.32952 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Epinastine 500micrograms/ml eye drops | £9.90 | 5 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.